Table 1.

Clinical information and serology of fingolimod-treated group

Patient	Sex	Age (years)	Disease duration (years)	EDSS	Vaccine	Test method	Antibody titer (U/ml)	Titer cut-off (U/ml)	Test result	Time vaccine-test (days)	WBC (× 109/l)	Lymphocytes (× 109/l)	Therapy duration	Previous IS
1	F	36.6	12.5	1.5	BNT162b2	CLIA	0.40	1.00	Negative	48	4.50	0.50	7.26	No
2	F	68.4	27.9	4.5	BNT162b2	ECLIA	64.29	0.80	Positive	36	2.90	0.40	3.16	No
3	F	57.8	19.0	3.5	BNT162b2	CLIA	4.40	7.10	Negative	23	5.31	0.55	8.01	No
4	M	26.9	6.0	1.0	BNT162b2	CLIA	58.00	NA	Positive	16	4.64	0.45	4.90	No
5	F	33.2	5.9	1.0	BNT162b2	CLIA	1.85	10.00	Negative	14	2.54	0.35	3.60	No
6	M	33.2	8.9	2.0	BNT162b2	CLIA	4.10	0.80	Positive	59	3.84	0.32	6.44	Yes
7	F	47.8	14.0	1.5	BNT162b2	ECLIA	0.74	NA	Negative	44	3.36	0.99	4.09	No
8	F	48.9	23.0	2.0	BNT162b2	CLIA	56.20	15.00	Positive	17	2.04	0.31	8.58	Yes
9	M	49.6	4.3	2.5	BNT162b2	CLIA	181.00	15.00	Positive	14	6.44	0.95	1.35	Yes
10	F	42.2	8.0	1.5	BNT162b2	CLIA	448.00	33.80	Positive	45	3.20	0.40	2.82	No
11	F	53.9	22.0	6.0	BNT162b2	CLIA	0.00	NA	Negative	37	6.59	0.87	5.96	No
12	M	47.4	23.9	1.5	BNT162b2	CLIA	107.30	50.00	Positive	40	3.80	0.38	1.91	No
13	F	40.9	17.3	1.5	BNT162b2	CLIA	7.13	1.00	Positive	16	5.93	0.55	6.56	No
14	F	18.2	5.1	1.0	mRNA-1273	CLIA	169.00	15.00	Positive	43	5.80	0.76	2.63	No
15	F	40.2	2.4	1.5	BNT162b2	CMIA	1.20	7.10	Negative	21	3.50	0.30	1.93	No
16	F	57.3	20.0	6.5	BNT162b2	CMIA	14.70	7.10	Positive	71	5.04	0.40	4.49	No

WBC white blood cells count, IS immunosuppressants—i.e. cyclophosphamide, mitoxantrone, ECLIA electrochemiluminescence immunoassay, CLIA chemiluminescence immunoassay, CMIA chemiluminescence microparticle immunoassay